Franco Morelli
A5052289386- Renal cell carcinoma treatment
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Prostate Cancer Treatment and Research
- Bladder and Urothelial Cancer Treatments
- Renal and related cancers
- Testicular diseases and treatments
- Economic and Financial Impacts of Cancer
- Cancer Treatment and Pharmacology
- Radiopharmaceutical Chemistry and Applications
- Cancer, Lipids, and Metabolism
- Urinary and Genital Oncology Studies
- Cancer Diagnosis and Treatment
- Sarcoma Diagnosis and Treatment
- Inflammatory Biomarkers in Disease Prognosis
- Lung Cancer Treatments and Mutations
- Head and Neck Cancer Studies
- Urologic and reproductive health conditions
- Pancreatic and Hepatic Oncology Research
- Neuroblastoma Research and Treatments
- Multiple Myeloma Research and Treatments
- Organ Transplantation Techniques and Outcomes
- Glioma Diagnosis and Treatment
- Multiple and Secondary Primary Cancers
- Radiomics and Machine Learning in Medical Imaging
Casa Sollievo della Sofferenza
2016-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2016-2025
University of Molise
2022-2024
Università Cattolica del Sacro Cuore
2023
Kantonsspital Graubünden
2018
University of Bern
2018
University Hospital of Bern
2018
University of Zurich
2018
Kantonsspital St. Gallen
2018
Heinrich Heine University Düsseldorf
2018
BackgroundPlatinum-based chemoradiation (CCRT) is the standard treatment for Locally Advanced Head and Neck Squamous-Cell Carcinoma (LAHNSCC). Cetuximab/RT (CET/RT) an alternative option to CCRT. The efficacy of induction chemotherapy (IC) followed by compared alone has not been demonstrated in randomized clinical trials. goals this phase II-III trial were assess: (i) overall survival (OS) IC versus no-induction (no-IC) (ii) Grade 3–4 in-field mucosal toxicity CCRT CET/RT. present paper...
Background: Despite the survival advantage, not all metastatic renal cell carcinoma (mRCC) patients achieve a long-term benefit from immunotherapy. Moreover, identification of prognostic biomarkers is still an unmet clinical need. Methods: This multicenter retrospective study investigated role peripheral-blood inflammatory indices and factors to develop novel score in mRCC receiving at least second-line nivolumab. The complete blood count before first cycle therapy was assessed by...
ABSTRACT Background Recently, a plethora of novel systemic agents have been incorporated into the therapeutic armamentarium advanced urothelial carcinoma (aUC). The antibody–drug conjugate (ADC), enfortumab vedotin (EV), has demonstrated relevant clinical benefit in patients with aUC refractory to platinum and immune‐checkpoint inhibitor (ICI) therapy. Our study provides retrospective, international, real‐world analysis comparing effectiveness EV chemotherapy this setting. Methods data were...
Purpose Residual lesions after chemotherapy are frequent in metastatic seminoma. Watchful waiting is recommended for < 3 cm as well fluorodeoxyglucose (FDG) positron emission tomography (PET)–negative ≥ cm. Information on the optimal management of PET-positive residual lacking. Patients and Methods We retrospectively identified 90 patients with seminoma chemotherapy. elevated α-fetoprotein or nonseminomatous histology were excluded. analyzed post-PET its impact relapse survival calculated...
Reliable and affordable prognostic predictive biomarkers for urothelial carcinoma treated with immunotherapy may allow patients' outcome stratification drive therapeutic options. The SAUL trial investigated the safety efficacy of atezolizumab in a real-world setting on 1004 patients locally advanced or metastatic who progressed to one three prior systemic therapies.Using Italian cohort 267 patients, we role neutrophil-to-lymphocyte ratio (NLR) immune-inflammation index (SII) best performing...
6004 Background: Platinum-based CRT is the standard treatment for LASCCHN. CET/RT superior to RT alone and it an alternative CRT. Induction TPF resulted be cisplatin/5fluorouracil but its efficacy when added concomitant demonstrated. We designed this open-label multicenter 2x2 factorial study assess 2 primary endpoints: 1) overall survival (OS) of induction vs. no induction; 2) Grade 3-4 in-field mucosal toxicity (already presented at ASCO 2013). Methods: 421 patients with LASCCHN oral...
Background Immune-checkpoint inhibitors (ICIs) have significantly improved metastatic renal cell carcinoma (mRCC) prognosis, although their efficacy in patients with bone metastases (BMs) remains poorly understood. We investigated the prognostic role of natremia pretreated RCC BMs receiving immunotherapy. Materials and methods This retrospective multicenter study included nivolumab as second-line therapy or beyond. Inclusion criteria involved baseline sodium levels (pre-ICI) after 4 weeks...
<i>Background:</i> Alexithymia is likely to be involved in the pain experience of cancer patients, but extent which psychological interventions may modify both and alexithymia unclear. <i>Methods:</i> A group 52 consecutive patients were enrolled a 6-month multicomponent intervention trial, compared control who received standard medical care. Validated scales for pain, alexithymia, coping with disease, illness behavior, distress, psychosocial functioning administered...
The coronavirus disease 2019 (COVID-19) pandemic has become a public health emergency affecting frail populations, including patients with cancer. This poses the question of whether cancer treatments can be postponed or modified without compromising their efficacy, especially for highly curable cancers such as germ cell tumors (GCTs).To depict state-of-the-art management GCTs during COVID-19 pandemic, survey 26 questions was circulated by e-mail among physicians belonging to three...
613 Background: NIVO showed an increased on OS in pre-treated mRCC. The introduction of metastasis SBRT could improve the clinical outcomes. NIVES Study evaluated efficacy and safety combination with II III line mRCC pts. Methods: This is a phase II, single arm, multicentre study pts PD after ≤2 prior anti-angiogenic therapies measurable metastatic sites, at least one suitable for SBRT. received hypofractionated radiation 1 lesion dose 10 Gy/3 fractions 7 days from first infusion NIVO. given...
The present study evaluates the utility of NGS analysis circulating free DNA (cfDNA), which incorporates small amounts tumor (ctDNA), at diagnosis or disease progression (PD) in NSCLC patients.
The upfront treatment of metastatic renal cell carcinoma (mRCC) has been revolutionized by the introduction immune-based combinations. role cytoreductive nephrectomy (CN) in these patients is still debated. ARON-1 study (NCT05287464) was designed to globally analyze real-world data mRCC receiving first-line immuno-oncology This sub-analysis focused on or delayed partial radical CN three geographical areas (Western Europe, Eastern America/Asia).We conducted a multicenter retrospective...